Search
Veltuzumab
go.drugbank.com/drugs/DB05656InvestigationalVeltuzumab is a monoclonal antibody which, as of October 2009, is undergoing Phase I/II clinical trials for the treatment of non-Hodgkin's lymphoma.
LY3884961
go.drugbank.com/drugs/DB17070InvestigationalLY3884961 (previously PR001) is being developed by Prevail Therapeutics as a single-dose gene therapy for patients with Parkinson's disease and Gaucher disease.[L43468]
Risuteganib
go.drugbank.com/drugs/DB14911InvestigationalRisuteganib is under investigation in clinical trial NCT02348918 (Phase 2 Randomized Clinical Trial of LuminateĀ® as Compared to AvastinĀ® in the Treatment of Diabetic Macular Edema).
ATL1102
go.drugbank.com/drugs/DB04997InvestigationalATL1102 is a second-generation antisense inhibitor of CD49d, an immunesystem protein known as VLA-4, an immune cell molecule. It works by entering cells and targeting genes.
Ontamalimab
go.drugbank.com/drugs/DB15298InvestigationalOntamalimab is under investigation in clinical trial NCT03627091 (Efficacy and Safety Study of SHP647 as Maintenance Treatment in Participants With Moderate to Severe Crohn's Disease (CARMEN CD 307)).
Dazostinag
go.drugbank.com/drugs/DB18889InvestigationalDazostinag is under investigation in clinical trial NCT04420884 (A Study of Dazostinag as Single Agent and Dazostinag in Combination With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors
Strontium malonate
go.drugbank.com/drugs/DB05732InvestigationalStrontium malonate is being developed as a novel orally available pharmaceutical for the treatment and prevention of osteoporosis. It is being developed by Osteologix Inc.
mRNA-3351
go.drugbank.com/drugs/DB17718ExperimentalDeveloped by Moderna, it is currently being investigated as the treatment for Crigler-Najjar syndrome
Natural Killer Cell
go.drugbank.com/drugs/DB15721InvestigationalNatural Killer (NK) cells originate and differentiate from hematopoietic stem cells through various signalling pathways involving cytokines and interleukins. These cells arise from CD34+ lymphoid progenitors and comprise 10-15% of all ly...
Cixutumumab
go.drugbank.com/drugs/DB12250InvestigationalCixutumumab has been used in trials studying the treatment of Lung Cancer, Malignant Neoplasm, Leukemia, Mast-Cell, Non-Small-Cell Lung Carcinoma, and Adenocarcinoma of the Prostate.